Diasisita Tablet 50/500 mg
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
Aprogen Biosciences, Inc.
MFDS item code 201506650 · Approved 2015.09.21
This product's status changed to Approval withdrawn on 2023.08.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in patients with type 2 diabetes. It is administered initially when there is no prior experience with diabetes medication treatment and blood sugar control is difficult with monotherapy. Additionally, it is used when sufficient effect is not achieved with monotherapy with either metformin or sitagliptin, or when substituting treatment with both drugs. This medication can also be taken in conjunction with metformin in cases where blood sugar control is difficult due to the combination therapy with sulfonylureas, or metformin and thiazolidinediones. It helps in blood sugar management when combined with insulin and metformin when blood sugar control is not sufficient. This medication is effective in improving blood sugar control by complementing various stages of treatment.
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is one tablet of this medicine 50/500 mg twice daily. The dose may be increased to one tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other condition that may increase the risk of lactic acidosis, provided that the following dosage adjustments are made. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).
This medication consists of sitagliptin and metformin and is used for the treatment of diabetes. When taking this medication, there can be severe allergic reactions, so if symptoms such as skin rash, shortness of breath, or swelling of the face or neck occur, stop taking it immediately and consult a doctor. Additionally, this medication can rarely cause severe pancreatitis, so if sudden abdominal pain, vomiting, or nausea occurs, inform healthcare providers immediately. Patients with severely impaired heart or kidney function, those with acute infections or dehydration, those with severe liver disease, and women who are pregnant or breastfeeding should not take this medication. During treatment, regular monitoring of kidney function is necessary, and discontinuation of the drug is required if kidney function declines. A rare but life-threatening condition called lactic acidosis may occur, so if severe fatigue, muscle pain, shortness of breath, or abdominal pain appears, visit the hospital immediately. This medication carries a risk of hypoglycemia, so caution is required when skipping meals or engaging in vigorous exercise, and more attention should be paid to hypoglycemic symptoms when taken with other antihyperglycemic agents. Alcohol consumption may increase the risk of side effects, so it is advisable to avoid excessive drinking during treatment. If undergoing surgery or tests involving radiocontrast agents, inform healthcare providers of this medication beforehand, and temporarily discontinue the medication if necessary. During treatment with this medication, regular blood tests, kidney function tests, and vitamin B12 level checks are important for monitoring health status. Elderly patients should be managed more carefully as kidney function may decline, and dose adjustments may be necessary. The safety and efficacy of this medication have not been established in children and adolescents, so it should not be used in these populations. If blisters appear on the skin or severe joint pain occurs during treatment, consult a doctor immediately. There may be interactions with other drugs, so if taking other medications, be sure to inform healthcare providers.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia accompanied by severe and disabling pain, herpes gestationis, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be kept in a sealed container to prevent air or moisture exposure, and it is best stored at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain its effectiveness and prevents deterioration.
Pink oval film-coated tablet
28 tablets/PTP, 56 tablets/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate · Metformin Hydrochloride
Prescription medication · Combination
Aprogen Biosciences, Inc.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.